Pharmally Scandal

Also known as: The Pharmally scandal — the standard styling · The Pharmally hearings — the Senate proceedings at the scandal's core · The Pharmally procurement controversy — the descriptive label in procurement literature · The Pharmally Pharmaceutical Corporation case — the docket styling in the later court records

Government

Definition

The Pharmally Scandal is the Philippine procurement controversy that broke in August 2021 over pandemic-supply contracts awarded to Pharmally Pharmaceutical Corporation — a company incorporated on September 4, 2019 with paid-up capital of ₱625,000 that became the government’s biggest pandemic supplier, drawing nine contracts worth ₱8.68 billion through the Procurement Service of the DBM (PS-DBM) for personal protective equipment, surgical masks, face shields, and RT-PCR test kits, and — by the count of the Right to Know, Right Now! coalition, reported by the Philippine Center for Investigative Journalism — some ₱10.85 billion in pandemic contracts overall once purchases through the DOH and the DOTr-PNR are counted. (Wikipedia — Pharmally scandal, Wikipedia — Senate Blue Ribbon Committee) The purchases were funded under the Bayanihan to Heal as One and Bayanihan to Recover as One Acts, and the Senate’s inquiry traced them to ₱41.4 billion in DOH funds transferred to the PS-DBM — a figure this wiki’s Procurement Service entry carries as ₱42.4 billion from its own source — where then-officer-in-charge Lloyd Christopher Lao signed the Pharmally contracts, and where the Service bought face masks at ₱27.22 each and face shields at ₱120, prices senators condemned against later suggested retail prices. (Wikipedia — Pharmally scandal, Wikipedia — Lloyd Christopher Lao, GMA News, Wikipedia — COVID-19 pandemic)

The Senate Blue Ribbon Committee investigated in 2021–2022 under Chair Richard Gordon — eighteen hearings, contempt citations, and the detention of company officers — and its 113-page partial draft report, signed by only nine senators, proposed charges reaching to President Rodrigo Duterte and Health Secretary Francisco Duque III, but never reached the plenary before the 18th Congress ended. (Wikipedia — Pharmally scandal, Wikipedia — Senate Blue Ribbon Committee) The subsequent record is a matter of courts and prosecutors: Ombudsman findings recommending graft counts against Lao, PS-DBM officials, and Pharmally executives in August 2023; the May 2024 order indicting and dismissing Duque and Lao; Sandiganbayan warrants and bail in September 2024; and the Supreme Court’s March 19, 2024 ruling voiding the committee’s contempt and arrest orders against two Pharmally resource persons — the decision this wiki’s Senate Blue Ribbon Committee entry documents. No conviction or acquittal appears in the documented record, and every person named remains presumed innocent on the unresolved charges. (Wikipedia — Pharmally scandal, Supreme Court — Pharmally contempt ruling)

Identities

Source Type	Identity
Wikipedia	Pharmally scandal
Wikidata	Pharmally scandal (Q113615040)
DBpedia	Pharmally_scandal
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings (LCSH)	N/A
MeSH	N/A
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	Pharmally Pharmaceutical Corporation scandal 2021 Philippines pandemic procurement PS-DBM face masks face shields 8.68 billion 10.85 billion Senate Blue Ribbon Gordon Lao Michael Yang Duque Ombudsman Sandiganbayan Bayanihan
ConceptNet	N/A
OpenCyc	N/A

Also Known As

The Pharmally scandal — the standard styling
The Pharmally hearings — the Senate proceedings at the scandal’s core
The Pharmally procurement controversy — the descriptive label in procurement literature
The Pharmally Pharmaceutical Corporation case — the docket styling in the later court records

Examples and Analogies

₱625,000 against ₱8.68 billion: the scandal’s arithmetic lesson — a firm capitalized at six figures signing pandemic contracts in ten, and topping the GPPB’s supplier list by May 2020 — the disparity that made Pharmally this wiki’s PhilGEPS entry’s standing example that registration and posting systems do not, by themselves, outwork collusion. (Wikipedia — Pharmally scandal)
Emergency procurement’s shadow route: the DOH did not bid these goods itself — it transferred tens of billions to the PS-DBM, whose bidding exemption this wiki’s Procurement Service entry documents, and the Service bought — the delegation chain the scandal made famous. (GMA News, Wikipedia — Pharmally scandal)
Verified record data:
Company: Pharmally Pharmaceutical Corporation, incorporated September 4, 2019; paid-up capital ₱625,000; offices at Fort Victoria Tower B, Taguig
Recorded ownership: Huang Tzu Yen (Singaporean, chair, 40%), Mohit Dargani (secretary/treasurer, 30%), Linconn Ong (director, 16%), Twinkle Dargani (president, 10%), Justine Garado (director, 4%); Lin Wei Xiong financial manager in Dubai
The Yang connection: Michael Yang, President Duterte’s former economic adviser, denied formal ties but admitted the firm sought his “assistance”; a 2017 Davao City video showed him introducing Pharmally officials to then-Mayor Duterte; Huang Tzu Yen described Yang as financier and guarantor to Chinese suppliers; a December 2024 OCCRP investigation reported Yang and Lin Wei Xiong bought US$20 million of Dubai real estate
Contracts: nine PS-DBM contracts worth ₱8.68 billion signed by Lloyd Christopher Lao, officer in charge from January 2, 2020; ₱10.85 billion overall by the Right to Know, Right Now! coalition count (PS-DBM, DOH, DOTr-PNR); runners-up among suppliers: Xuzhou Construction (₱1.9 billion), Phil Pharmawealth (₱1.81 billion)
Items: PPE sets, surgical masks, face shields, RT-PCR test kits
Whistleblower record: September 2021 testimony that deformed, soiled, and substandard face shields were repacked, with 2020 certificates replaced by 2021 ones; Commission auditor Illuminada Sebial testified she was denied access to Pharmally’s financial documents; employee Krizle Mago told the Senate on September 24, 2021 that the firm “swindled” the government, then recanted on October 24, 2021 as a “pressured response”
Hearings: Senate Blue Ribbon Committee, Chair Richard Gordon, 18 hearings, 2021–2022; the 113-page partial draft report signed by only nine senators — Gordon, Drilon, De Lima, Hontiveros, Lacson, Pacquiao, Pangilinan, Pimentel, Recto
Contempt record: September 2021 arrest orders against both Darganis, Mago, Garado, Ong, and Yang; the Dargani siblings cited October 19, 2021 and arrested November 15, 2021 as they sought to leave Davao by chartered flight; Ong arrested September 2021; Twinkle Dargani released January 2022 on health grounds; Ong and Mohit Dargani released June 2, 2022 by Senate President Vicente Sotto III to avoid illegal-detention exposure
Ombudsman record: August 14, 2023 — three graft counts each recommended against Lao, PS-DBM officials Warren Rex Liong and Paul Jasper de Guzman, and the Pharmally executives; one count against four others including Mago; seven PS-DBM officials found guilty of gross neglect of duty; May 2024 resolution adding Lin Wei Xiong and denying reconsideration; May 10, 2024 — Duque and Lao ordered indicted for violating Section 3(e) of the Anti-Graft law over the ₱41-billion transfer and ordered dismissed with forfeiture and perpetual disqualification
Court record: September 12, 2024 Sandiganbayan warrant against Lao (₱90,000 bail), arrested September 18 in Davao and released on bail; Duque posted bail; March 19, 2024 — the Supreme Court voided the Blue Ribbon’s contempt and arrest orders against Pharmally resource persons Linconn Ocampo and Mohit Sadhwani (G.R. Nos. 257401-02)
(Wikipedia — Pharmally scandal, Supreme Court — Pharmally contempt ruling, Wikipedia — Senate Blue Ribbon Committee)

Usage Scenarios

1. Following the Accountability Record

The outcomes live in the prosecutorial and judicial files — the Ombudsman’s 2023 findings and 2024 indictments, the Sandiganbayan warrants and bail of September 2024 — each documented at its stage, with no conviction or acquittal yet in the record and the presumption of innocence standing over every unresolved charge. (Wikipedia — Pharmally scandal, Wikipedia — Francisco Duque)

2. Studying the Contempt Power’s Limits

The scandal produced the leading modern ruling on legislative detention: Linconn Ocampo and Mohit Sadhwani v. Senate Blue Ribbon Committee (March 19, 2024), where the Supreme Court held a witness’s refusal to be sworn is not a refusal to give testimony, detention cannot be indefinite, and the arrest order lacked the Senate rules’ required concurrence — the ruling this wiki’s Blue Ribbon entry carries as the standing corrective on the committee’s coercive process. (Supreme Court — Pharmally contempt ruling)

3. Analyzing Emergency Procurement

The Bayanihan-era purchases showed what pandemic urgency did to the procurement chain — agencies transferring funds to the PS-DBM, common-use rules bending to agency-specific goods, and the eventual reform answer in the New Government Procurement Act of 2024 that this wiki’s PhilGEPS, Procurement Service, and GPPB entries document from their sides. (Wikipedia — COVID-19 pandemic, GMA News)

4. Tracing Corporate Beneficiaries

The Pharmally record — a thinly capitalized firm, an offshore-linked ownership roster with a Singaporean chair at 40 percent, a presidential adviser’s admitted “assistance,” and Dubai real estate in the aftermath — is the Philippine case study in following beneficial ownership to the beneficiaries, the discipline the 2024 procurement law’s beneficial-ownership registry answers. (Wikipedia — Pharmally scandal)

5. Assessing a Report That Died in Committee

The Blue Ribbon’s 113-page draft — signed by nine of a needed eleven, its Duterte and Duque recommendations never adopted by the plenary — is a study in the Senate’s internal thresholds: the signature rule that shaped the flood-control report’s fate in 2026 also stranded Pharmally’s in 2022. (Wikipedia — Pharmally scandal, Wikipedia — Senate Blue Ribbon Committee)

Strategies

Audit findings as the opening wedge: the senators’ August 2021 questioning ran from the COA-flagged DOH transfers and the PS-DBM’s unit prices — the pattern this wiki’s Procurement Service entry records — turning audit exception into public hearing. (GMA News)
Public hearing as record: with prosecution years away, the televised hearings preserved testimony — the Darganis’ detention, Mago’s admission and recantation, the auditor’s blocked access — that later cases and journalism worked from. (Wikipedia — Pharmally scandal)
Referral, not adjudication: the committee’s product was recommendations to the Ombudsman, which the 2023–2024 findings then pursued on the prosecutors’ own authority — the division of labor this wiki’s Blue Ribbon entry documents. (Wikipedia — Senate Blue Ribbon Committee)
Corporate forensics on the record: tracing incorporation dates, capital, ownership percentages, and guarantors — the SEC papers against the contract ledger — supplied the scandal’s evidentiary core. (Wikipedia — Pharmally scandal)
For researchers: quote each figure at its source — ₱8.68 billion for the nine PS-DBM contracts, ₱10.85 billion for the coalition count, ₱41.4 billion or ₱42.4 billion for the DOH transfer depending on the account — and keep every unresolved matter at its documented stage. (Wikipedia — Pharmally scandal, GMA News)

Security and Safety Measures

The presumption of innocence: the indicted officials and executives — Duque, Lao, the PS-DBM officers, the Pharmally officers — are charged, not convicted; the dismissals ordered by the Ombudsman in May 2024 are administrative findings under appeal in the ordinary course, and no criminal verdict stands in the record. (Wikipedia — Pharmally scandal, Wikipedia — Francisco Duque)
Due process inside the Senate itself: the Supreme Court’s 2024 ruling — sworn refusals are not testimony refusals, detention must be finite, concurrence rules bind — is the procedural safeguard the scandal left the legislature, and this wiki’s Blue Ribbon entry’s standing caution. (Supreme Court — Pharmally contempt ruling)
Auditor access as a control: the Sebial testimony — a Commission auditor denied the company’s papers — marks the audit-access failure the scandal exposed; the 2024 procurement law’s end-to-end audit-trail design is the systemic answer. (Wikipedia — Pharmally scandal)
Recantation discipline: Mago’s “swindled” admission of September 24, 2021, recanted exactly a month later, is the record’s warning that extracted statements are unstable evidence — the reason researchers cite both statements together or neither. (Wikipedia — Pharmally scandal)
For researchers: the money figures conflict at every level (₱8.68 billion, ₱10.85 billion, ₱11.5 billion in some accounts, ₱41.4 billion or ₱42.4 billion for the DOH transfer) — attribute each to its counter, and date every status to its document. (Wikipedia — Pharmally scandal, GMA News)

Historical Context

The scandal was born of the pandemic’s emergency economics. In 2020 the DOH, its procurement capacity overwhelmed, transferred some ₱41 billion to ₱42 billion to the PS-DBM — the central purchasing service this wiki’s Procurement Service entry documents — which bought pandemic goods at scarcity prices: face masks at ₱27.22, face shields at ₱120. Among its suppliers Pharmally Pharmaceutical Corporation, incorporated in September 2019 with ₱625,000 paid-up capital, rose fastest — topping the supplier rankings by May 2020 and signing ₱8.68 billion in contracts under the PS-DBM’s officer in charge, Lloyd Christopher Lao, funded by the Bayanihan laws’ appropriations. The Commission on Audit’s 2020 audit findings and the Senate’s August 2021 hearings — senators grilling DOH and DBM officials over the prices — put the name Pharmally before the public. (Wikipedia — Pharmally scandal, GMA News, Wikipedia — COVID-19 pandemic)

The Blue Ribbon investigation then became its own constitutional drama. The committee under Richard Gordon sat eighteen hearings, cited officers and associates in contempt, and detained the Dargani siblings and Linconn Ong through the winter of 2021–2022; President Duterte defended Michael Yang, accused the senators of publicity-seeking, and in October 2021 barred Cabinet officials from the hearings, calling the probe a “witch hunt” and “the Senate is not a criminal court.” The 113-page draft report — proposing betrayal-of-public-trust charges against Duterte over Yang’s appointment and plunder findings against Duque in the draft — fell two signatures short of the plenary threshold and died with the 18th Congress. The aftermath belongs to other institutions: the Ombudsman’s graft findings of August 2023, the Duque and Lao indictments and dismissals of May 2024, the Sandiganbayan warrants of September 2024, and the Supreme Court’s March 19, 2024 ruling voiding the contempt orders — while the procurement system the scandal discredited was rewritten by the New Government Procurement Act of 2024. (Wikipedia — Pharmally scandal, Wikipedia — Rodrigo Duterte, Supreme Court — Pharmally contempt ruling, Wikipedia — Senate Blue Ribbon Committee)

Challenges and Controversies

The Numbers That Do Not Agree

Every headline number has a rival: ₱8.68 billion for the nine PS-DBM contracts; ₱8.6 billion for the 2020 contracts; ₱10.85 billion for the coalition count across three procuring channels; ₱41.4 billion against ₱42.4 billion for the DOH-to-PS-DBM transfer. Each is honest at its own boundary of contracts, years, and agencies — the discipline of naming the counter that this entry and this wiki’s PhilGEPS and Procurement Service entries practice. (Wikipedia — Pharmally scandal, GMA News)

The Contempt Power on Trial

The detentions of 2021–2022 — the Darganis stopped at Davao, Ocampo and Sadhwani held for refusing to be sworn, Sotto’s June 2022 release order to avoid illegal-detention exposure — ended in the Supreme Court’s 2024 voiding of the committee’s orders, reopening the standing debate over a legislature’s power to jail that this wiki’s Blue Ribbon entry carries as the committee’s oldest controversy. (Supreme Court — Pharmally contempt ruling, Wikipedia — Pharmally scandal)

Presidential Protection and the Inquiry’s Limits

Duterte’s documented record — defending Yang, questioning the senators’ motives, barring Cabinet officials from October 2021, declining comment on the draft report in February 2022 — set the inquiry’s political boundary, and the report charging him never cleared the Senate’s own signature threshold; whether that was constitutional restraint or impunity remains the scandal’s central unresolved argument, recorded here at the level of what each side did. (Wikipedia — Pharmally scandal, Wikipedia — Rodrigo Duterte)

Indictment Is Not Verdict

The Ombudsman’s findings and the Sandiganbayan dockets are the accountability record’s strongest documents, but they are charges and administrative rulings, not judgments of guilt; Duque and Lao have answered through counsel and bail, the Pharmally officers deny the charges, and the presumption of innocence governs every unresolved matter — the register this entry holds throughout. (Wikipedia — Pharmally scandal, Wikipedia — Francisco Duque)

The Emergency That Excused the Rules

The deeper controversy is structural: the Bayanihan framework’s emergency procurement, the delegation to the PS-DBM, and scarcity pricing were the scandal’s enabling conditions — the reason the reform answer came as the New Government Procurement Act of 2024, with its audit trails and beneficial-ownership registry, rather than as prosecutions alone. (Wikipedia — COVID-19 pandemic, Wikipedia — Pharmally scandal)